Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
| Image |  |
|---|---|
| Description | article |
| Author/s |
author: Dirk Hose Hartmut Goldschmidt Katja Weisel |
| Publication date | May 28, 2019 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |